Sandoz, a Novartis division, has entered into an agreement with Gan & Lee to commercialize biosimilar versions of insulins used in patients with type 1 and type 2 diabetes.
The commercialization and supply agreement with Gan & Lee aims at bringing to market biosimilar versions of glargine, lispro and aspart — the three top insulin medicines by sales.
Gan & Lee is a leading insulin supplier headquartered in China with more than 20 years’ experience in insulins and production capacity with attractive cost of goods sold structures.
Under the terms of the agreement, Sandoz will be fully responsible for commercializing these medicines in the EU, United States, Switzerland, Japan, South Korea, Canada, Australia and New Zealand.
Gan & Lee will be responsible for manufacturing and development, with support from Sandoz, and shall adhere to the stringent manufacturing requirements established for Sandoz biosimilars. Other specific terms of the agreement are confidential.
“Across the world, people suffering from diabetes still face very real access challenges. In fact, U.S. patients have reported taking less insulin than recommended by their doctor because they couldn’t afford it — putting them at higher risk for serious complications,” Sandoz CEO, Richard Francis, said.”At Sandoz, we have significant experience disrupting and transforming marketplaces, and look forward to extending access for the more than 420 million people worldwide suffering from diabetes.”